Equities
Health CarePharmaceuticals and Biotechnology
  • Price (EUR)13.90
  • Today's Change-0.16 / -1.14%
  • Shares traded15.38k
  • 1 Year change-8.91%
  • Beta0.7422
Data delayed at least 15 minutes, as of May 06 2024 14:45 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Abivax SA is a clinical stage biopharmaceutical company focusing on the discovery, development and commercialization of anti-viral compounds and therapeutic vaccines against severe and life threatening infectious diseases. ABIVAX utilizes RNA-protein interaction interference and cytotoxic TH1 cell amplification to generate therapies to help patients clear viruses like HIV, HBV and HPV. The Company's product pipeline comprises ABX 203, which is the therapeutic vaccine candidate obtained from the Centre for Genetic Engineering and Biotechnology, Cuba (CIGB) and is intended for patients with chronic hepatitis B disease; and ABX196, the adjuvant for therapeutic vaccines, among others.

  • Revenue in EUR (TTM)0.00
  • Net income in EUR-147.74m
  • Incorporated2013
  • Employees40.00
  • Location
    Abivax SA7-11 Boulevard HaussmannPARIS 75009FranceFRA
  • Phone+33 153830963
  • Fax+33 494279261
  • Websitehttps://www.abivax.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Innate Pharma SA51.90m-7.57m178.30m179.00--3.43--3.44-0.0939-0.09390.64510.6420.2648--5.67289,949.70-3.86-8.83-4.87-12.1194.5093.17-14.59-55.55----0.6408--4.68-8.2786.94--10.50--
Cellectis SA8.55m-101.74m197.43m235.00--2.51--23.10-1.74-1.630.15461.100.0309--13.7136,362.81-39.24-24.08-60.81-30.69---64.64-1,270.92-308.24---5.080.5429---64.26-15.57-20.55---26.15--
Sensorion SA0.00-22.06m210.78m50.00--3.95-----0.2063-0.20630.000.17790.00-------51.64-35.12-71.66-46.97------------0.0794------4.94--126.45--
Euroapi SA1.02bn-189.70m274.90m3.67k--0.2957--0.2698-2.01-2.0110.739.780.60861.384.24277,705.10-11.34---15.93--16.15---18.63--0.6573--0.1955--3.87---1,164.67------
Nanobiotix SA30.06m-39.70m277.14m102.00------9.22-1.10-1.100.814-0.03910.3912--19.59294,686.30-51.67-54.11-120.56-80.68-----132.08-756.15---1.981.04----203.8830.40---7.81--
Carbios SA24.00k-27.22m394.19m134.00--1.68--16,424.49-2.03-2.030.001713.920.0001--0.7619179.10-11.20-9.92-12.13-10.77-4,783.33---113,433.30-3,365.229.43-23.970.1517---65.71-53.321.86--141.01--
Medincell SA10.85m-26.42m415.71m138.00------38.33-1.02-1.020.4086-0.89650.2605--6.8175,853.15-63.46-59.54-115.15-117.3660.4368.38-243.58-451.26---4.291.69--141.788.96-29.04---2.87--
Valneva SE153.71m-101.43m478.28m684.00--3.72--3.11-0.7343-0.73431.110.9240.28432.544.69224,726.60-18.76-15.39-31.44-25.0634.3735.94-65.99-34.951.37-3.570.6195---57.466.3429.21--35.18--
Guerbet SA785.69m23.87m480.36m2.92k21.131.275.770.61141.801.8062.1529.970.79970.59835.80269,071.902.261.402.961.8678.0176.022.821.821.215.620.503557.824.30-0.0993158.05-12.615.23-10.07
Boiron SA493.25m35.83m592.16m2.81k16.361.4910.701.202.062.0628.4122.670.7151.405.26175,533.104.924.596.165.7672.6074.026.886.801.50--0.033853.86-7.67-3.98-19.80-9.01-17.68-1.42
Abivax SA0.00-147.74m884.78m40.00--4.51-----3.35-3.350.003.120.00----0.00-73.79-65.49-96.88-94.75-----------8.050.2206-------111.52---19.06--
Biophytis SA0.00-17.03m1.11bn26.00---------6.55-6.550.00-1.480.00-------100.31-97.52-1,481.81-487.25-----------12.25--------29.69--14.25--
Vetoquinol SA529.27m55.56m1.12bn2.48k20.152.1213.902.124.704.7044.7344.530.78762.395.74213,157.908.277.0910.449.4050.3161.2710.508.841.86--0.032416.48-1.957.5415.768.915.9812.11
Data as of May 06 2024. Currency figures normalised to Abivax SA's reporting currency: Euro EUR

Institutional shareholders

10.71%Per cent of shares held by top holders
HolderShares% Held
Deep Track Capital LPas of 30 Sep 20232.68m4.25%
VHCP Management LLCas of 31 Dec 20232.61m4.15%
HBM Partners AG (Investment Management)as of 31 Dec 2023761.00k1.21%
Pictet Asset Management SAas of 31 Dec 2023174.76k0.28%
Saint Olive Gestion SNCas of 29 Dec 2023109.29k0.17%
LSP Advisory BVas of 31 Dec 202398.93k0.16%
HSBC Global Asset Management (France) SAas of 29 Feb 202498.65k0.16%
BlackRock Fund Advisorsas of 04 Apr 202477.62k0.12%
CPR Asset Management SAas of 31 Mar 202473.06k0.12%
BlackRock Advisors (UK) Ltd.as of 04 Apr 202455.26k0.09%
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.